RT Journal Article
SR Electronic
T1 How to predict relapse in leukemia using time series data: A comparative in silico study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.12.04.20243907
DO 10.1101/2020.12.04.20243907
A1 Hoffmann, Helene
A1 Baldow, Christoph
A1 Zerjatke, Thomas
A1 Gottschalk, Andrea
A1 Wagner, Sebastian
A1 Karg, Elena
A1 Niehaus, Sebastian
A1 Roeder, Ingo
A1 Glauche, Ingmar
A1 Scherf, Nico
YR 2021
UL http://medrxiv.org/content/early/2021/05/21/2020.12.04.20243907.abstract
AB Risk stratification and treatment decisions for leukemia patients are regularly based on clinical markers determined at diagnosis, while measurements on system dynamics are often neglected. However, there is increasing evidence that linking quantitative time-course information to disease outcomes can improve the predictions for patient-specific treatment responses.We designed a synthetic experiment to compare different computational methods with respect to their ability to accurately predict relapse for chronic and acute myeloid leukemia treatment. Technically, we used clinical reference data to first fit a model and then generate de novo model simulations of individual patients’ time courses for which we can systematically tune data quality (i.e. measurement error) and quantity (i.e. number of measurements). Based hereon, we compared the prediction accuracy of three different computational methods, namely mechanistic models, generalized linear models, and deep neural networks that have been fitted to the reference data.Our results show that data quality has a higher impact on prediction accuracy than the specific choice of the particular method. We further show that adapted treatment and measurement schemes can considerably improve the prediction accuracy.Our proof-of-principle study highlights how computational methods and optimized data acquisition strategies can improve risk assessment and treatment of leukemia patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Technische Universitaet Dresden, Faculty of Medicine Carl Gustav Carus, MeDDrive grant no. 60470 to NS.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:see original publicationsAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe patient data for the AML patients are published in [Hoffmann2020] and can be found here: https://doi.org/10.6084/m9.figshare.12871777.v1 The CML patient data will be provided upon request to the correspondent author (Ingmar Glauche). Source code is available at https://zenodo.org/record/4293490#.X8DznMtKg-Q https://doi.org/10.6084/m9.figshare.12871777.v1